BridgeBio Oncology Therapeutics, Inc. SEC filings BBOT
BridgeBio Oncology Therapeutics, Inc. has 185 filings in SEC EDGAR's recent list, going back to Dec 20, 2023. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (officer or director change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Sep 10, 2026 | — |
| EFFECT | Filing | Sep 8, 2026 | — |
| EFFECT | Filing | May 4, 2026 | — |
| EFFECT | Filing | Sep 10, 2025 | — |
| CORRESP | Letter to the SEC | Sep 8, 2025 | — |
| UPLOAD | Letter from the SEC | Sep 3, 2025 | — |
| EFFECT | Filing | Aug 19, 2025 | — |
| 425 | Current report | Aug 4, 2025 | — |
| 425 | Form 425 | Jul 21, 2025 | — |
| 425 | Current report | Jul 11, 2025 | — |
| EFFECT | Filing | Jul 10, 2025 | — |
| CORRESP | Letter to the SEC | Jul 9, 2025 | — |
| CORRESP | Letter to the SEC | Jul 1, 2025 | — |
| UPLOAD | Letter from the SEC | Jun 27, 2025 | — |
| CORRESP | Letter to the SEC | Jun 20, 2025 | — |
| UPLOAD | Letter from the SEC | Jun 11, 2025 | — |
| DRSLTR | Filing | May 30, 2025 | — |
| DRS/A | Filing | May 30, 2025 | — |
| UPLOAD | Letter from the SEC | May 13, 2025 | — |
| DRS | Filing | Apr 15, 2025 | — |
| DRSLTR | Filing | Apr 14, 2025 | — |
| 425 | Form 425 | Mar 6, 2025 | — |
| 425 | Current report | Mar 3, 2025 | — |
| 425 | Current report | Feb 28, 2025 | — |
| EFFECT | Filing | Feb 8, 2024 | — |
| CERT | Filing | Feb 8, 2024 | — |
| 8-A12B | For registration of certain classes | Feb 8, 2024 | — |
| CORRESP | Letter to the SEC | Feb 7, 2024 | — |
| CORRESP | Letter to the SEC | Feb 7, 2024 | — |
| CORRESP | Letter to the SEC | Feb 6, 2024 | — |
| UPLOAD | Letter from the SEC | Feb 6, 2024 | — |
| CORRESP | Letter to the SEC | Feb 2, 2024 | — |
| UPLOAD | Letter from the SEC | Jan 23, 2024 | — |
| CORRESP | Letter to the SEC | Jan 18, 2024 | — |
| UPLOAD | Letter from the SEC | Jan 10, 2024 | — |
| DRS | Filing | Dec 20, 2023 | — |
Showing 36 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BBOT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1869105
- Former names
- Helix Acquisition Corp. II (until Aug 6, 2025)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.